Introduction {#s1}
============

Since the publication of the human genome sequence, understanding the functional complexity of the genome has become a primary goal of high-throughput experimental research. By definition, AS contributes to proteomic complexity but it has also been suggested that AS is a major driver of phenotypic complexity, though this role remains unproven [@pone.0005001-Blencowe1]--[@pone.0005001-Tress1]. By splicing several combinations of exons into different transcripts, AS generates, from a single gene, multiple isoforms of a protein with potentially diverse functions. Not only has AS been invoked as an explanation for our complexity as a species, detection of splice isoforms has been associated with the cause and progression of certain diseases. Alternative splicing is associated with a wide variety of conditions including bipolar disorder, schizophrenia, cancer, diabetes, multiple sclerosis, cystic fibrosis and asthma (for a review see Wang & Cooper [@pone.0005001-Wang1]). Splice isoforms may be functionally relevant in disease or may act as biomarkers - indicators of normal or altered biological processes or pharmacological response to a therapeutic intervention [@pone.0005001-Atkinson1]. Biomarkers such as disease-specific AS isoforms can serve as indicators of disease susceptibility as well as diagnostic and prognostic markers.

Alternative splicing occurs in many cell types including platelets - hemostatic, anucleate cells derived from megakaryocytes. Although devoid of a nucleus, they retain low levels of mRNA which undergo translation. They have an intact spliceosome and cellular activation of platelets induces splicing of pre-mRNAs including IL-1β [@pone.0005001-Denis1] and tissue factor (TF) [@pone.0005001-Schwertz1]. Platelets are primarily involved in thrombus formation but their functions also extend to pathophysiological processes such as host defense, regulation of vascular tone, inflammation and tumor growth [@pone.0005001-Harrison1]. Splice isoforms in platelets have been implicated in the variable response to aspirin [@pone.0005001-Censarek1] and as possible antithrombotic drug targets [@pone.0005001-Newland1]. Blood-based biomarker discovery would provide minimally invasive and sensitive detection of disease-associated molecular changes. Disease biomarkers, serving as specific diagnostic signatures of phenotype, could improve drug discovery and facilitate the development of modern, personalized clinical applications.

To date, efforts to detect AS events have relied primarily on sequencing mature mRNA species. The bulk of our knowledge comes from mapping expressed sequence tags (ESTs) to the genome. However, this approach is hindered by the lack of EST coverage with few ESTs sequenced for most genes [@pone.0005001-Modrek1] and the central region of mRNAs inadequately represented. More recently, exon arrays have been developed to determine genome-wide exon expression levels. This technology detects differences in expression across a gene to infer the presence of alternative splicing events, but cannot determine unambiguously what combination of exons is present on a single mRNA. The inference of AS is confounded somewhat by the variable hybridization intensities of neighboring probe sets within a sample and differential gene expression between samples. Ultra high-throughput sequencing addresses some of the problems encountered with previous methods of AS detection [@pone.0005001-Marioni1]. This approach can identify many alternative splice variants if sufficient sequence reads are carried out [@pone.0005001-Wang2], [@pone.0005001-Sultan1]. As longer sequence reads become available, it will be possible to identify considerable structure flanking a given AS event.

The capacity to discover AS events at the mRNA level is very powerful and mRNAseq has provided evidence for AS occurring in 100% of multi-exonic human genes [@pone.0005001-Wang2]. It remains unclear how many of the splice isoforms identified are sufficiently stable to result in translation products. Studying the proteome circumvents this issue - a recent study by Tress and coworkers for example, demonstrated the presence of translated AS isoforms in *Drosophila melanogaster* [@pone.0005001-Tress2]. The development of new, innovative discovery approaches based on protein expression will greatly enhance the existing methodologies.

Mass spectrometry (MS) has emerged as a highly effective analytical technique capable of detecting vast numbers of peptides in complex mixtures. This is achieved by mapping spectra generated from a MS experiment to a database of known or, more commonly, theoretically derived spectra to infer the peptide sequence. Exon skip splice isoforms are characterized by the peptides spanning the exon-exon junction of a novel splicing event. To detect these peptides, we generate a database containing the theoretical exon-skip junction peptides across a genome. We then use standard MS search tools to identify junction peptides that represent exon skip events in MS/MS spectra by comparison with this database ([Fig. 1](#pone-0005001-g001){ref-type="fig"}). Here, we show that this approach can detect novel exon skip events in human platelets and verify a number of these at the mRNA level.

![Workflow for the identification of novel exon skip events.\
A rectangle represents a program, rhombus represents a program output, cylinder represents a data source and circle represents a program input.](pone.0005001.g001){#pone-0005001-g001}

Results {#s2}
=======

Database design {#s2a}
---------------

The strategy we employed to generate the database (which we call SkipE) is outlined in [Figure 1](#pone-0005001-g001){ref-type="fig"}. Transcript and exon data were extracted from Ensembl v46 [@pone.0005001-Hubbard1] for all 22,680 annotated human protein-coding genes. To create exon skip junctions *in silico,* a gene containing multiple transcripts was first reduced to a single 'full length transcript' ([Fig. 2a](#pone-0005001-g002){ref-type="fig"}) as described in [Materials and Methods](#s4){ref-type="sec"}.

![Generation and usage of the SkipE database.\
(A) Generation of representative transcripts. Each box represents an exon and each line is an intron. i), ii) and iii) represent transcripts from a single gene. iv) shows the full length representative transcript used to generate the junction peptides. (B) Structure of a junction peptide. The top two boxes represent the translated sequences of two separate, non-adjacent exons. The tryptic cleavage sites are represented by dashed vertical bars. The C-terminal sequence of the upstream exon from the final tryptic site is spliced to the N-terminus of the downstream exon and extends to the first tryptic cleavage site of the downstream exon.](pone.0005001.g002){#pone-0005001-g002}

All non-contiguous junction peptides in a 'full length transcript' were created such that the termini are trypsin cleavage sites ([Fig. 2b](#pone-0005001-g002){ref-type="fig"}). It is possible to design a database for other proteolytic enzymes but trypsin is by far the most commonly employed proteinase in proteomics experiments. Combinations of exons yielding junction peptides were constrained by the phase of the exons in order to keep the sequences within the correct reading frame. Phase describes the number of nucleotides upstream of an exon that are used to form a codon so that the length of the exon is a multiple of three. A previous study by Sorek *et al.* [@pone.0005001-Sorek1] showed, using coding sequence information from Genbank, that the majority of orthologous alternatively spliced exons conserved between human and mouse did not endure a frame shift. Furthermore, it is likely that many phase shifting splice events generate transcripts which are degraded *via* nonsense-mediated decay [@pone.0005001-Lewis1]. In order to detect only alternative splice events in which the correct reading frame is maintained, the phase of both exons joined by the alternatively spliced junction was calculated and only those junctions with exons of compatible phase were entered into the database.

Duplicate entries of the same junction peptide mapping to different genes were removed to eliminate ambiguity, since the source of such peptides could not be ascribed to a particular gene. This procedure yielded 307,030 junction peptides for the human genome. Previous genome-based studies, such as 6-frame translation of the genome, result in search spaces that are incompatible with high-throughput approaches. Genome-based methods that reduce the search space complexity, provide a powerful means to identify new protein-coding exons and genes but are not appropriate for direct mapping of exon skips since these junctions are derived from non-contiguous sequences [@pone.0005001-Tanner1]. The database we constructed, subject to the constraints described, generates a search space appropriate for the high-throughput MS/MS methods in use today and into the future. Further details on the composition of the human, mouse and rat databases are provided ([Table S1](#pone.0005001.s001){ref-type="supplementary-material"}).

The skipE database is in FASTA format and therefore suitable for use with any of the major search engines; in this case we employed SEQUEST [@pone.0005001-Eng1] combined with PeptideProphet and ProteinProphet for statistical validation of identifications [@pone.0005001-Keller1]. We chose a cutoff score of 0.9, a commonly used cutoff in MS/MS experiments [@pone.0005001-Bodenmiller1], for both tools. We then determined which junction-spanning peptides are novel and those which were previously described by comparing peptide sequences with the Alternative Splice Transcript Database (ASTD) [@pone.0005001-Stamm1]--[@pone.0005001-Thanaraj1] and the International Protein Index database (IPI) [@pone.0005001-Kersey1] using WU-BLAST (<http://blast.wustl.edu>). This also filters out junction peptides which are identical to sequences within "canonical" isoforms, whether they occur at exon boundaries or elsewhere.

Identification of platelet proteins and AS peptides {#s2b}
---------------------------------------------------

Platelet mass spectra were collected and compared with both the IPI and SkipE databases to identify peptides. The number of peptides and proteins identified in each database are shown in [table S2](#pone.0005001.s002){ref-type="supplementary-material"}. SEQUEST searching against IPI identified 6,292 unique peptides representing 1,122 unique proteins in the samples with a ProteinProphet probability score of P\>0.9. Since the SkipE database harbors peptide rather than protein sequences, ProteinProphet is inappropriate. Therefore, spectra identified by comparison with SkipE were validated using a PeptideProphet probability cut-off of 0.9 resulting in 1,297 unique protein identifications. Of these, 359 were represented by more than a single occurrence of the peptide in the dataset.

The spatial distribution of AS identifications closely mirrors that of the IPI data with the exception of the releasate ([Fig. 3a, b](#pone-0005001-g003){ref-type="fig"}). In this case, more skips were found in the activated than in the resting samples for the AS data. Although the activation step was very brief, this may indicate a tendency towards diversification of the exported proteome in response to platelet activation. Functionally, this would be advantageous since these cells must interact with the *milieu* and other cell types but cannot mount a transcriptomic response to stimuli. All identified proteins in both SkipE and IPI data were mapped to KEGG pathways using Pathway-Express [@pone.0005001-Draghici1] ([Table S3](#pone.0005001.s003){ref-type="supplementary-material"} and [S4](#pone.0005001.s004){ref-type="supplementary-material"}). In a typical MS/MS data analysis, protein identifications rely on multiple peptide identifications for any given protein. Since SkipE harbors isolated peptide sequences, we decided to focus further experiments on those AS events for which evidence of cognate gene expression was also obtained in the IPI analysis. Therefore, we constructed a list of 89 genes which represents the intersection of the AS and IPI datasets ([Table 1](#pone-0005001-t001){ref-type="table"}).

![Characteristics of the exon skip events detected in human platelets.\
(A) and (B) describe the distribution of the SkipE and IPI peptides respectively, across the different subcellular compartments for both resting and activated platelet samples.](pone.0005001.g003){#pone-0005001-g003}

10.1371/journal.pone.0005001.t001

###### Description of the 89 genes identified in both SkipE and IPI.

![](pone.0005001.t001){#pone-0005001-t001-1}

  Gene Symbol    Ensembl Gene ID      Exon ID 1         Exon ID 2                                      Description
  ------------- ----------------- ----------------- ----------------- ------------------------------------------------------------------------------
  ACLY           ENSG00000131473   ENSE00000898911   ENSE00000898879                               ATP-citrate synthase
  ACOX1          ENSG00000161533   ENSE00001222343   ENSE00001117984                      Acyl-coenzyme A oxidase 1, peroxisomal
  ACTN4          ENSG00000130402   ENSE00000895798   ENSE00000895787                                 Alpha-actinin-4
  ALOX12         ENSG00000108839   ENSE00000905333   ENSE00000887238                      Arachidonate 12-lipoxygenase, 12S-type
  AMPD2          ENSG00000116337   ENSE00001153152   ENSE00000913099                                 AMP deaminase 2
  AP1B1          ENSG00000100280   ENSE00000652055   ENSE00000652051                           AP-1 complex subunit beta-1
  APOB           ENSG00000084674   ENSE00000932268   ENSE00000718984                          Apolipoprotein B-100 precursor
  APOL1          ENSG00000100342   ENSE00000935990   ENSE00001369317                           Apolipoprotein-L1 precursor
  ARHGEF7        ENSG00000102606   ENSE00000686804   ENSE00000686825                     Rho guanine nucleotide exchange factor 7
  ARHGEF7        ENSG00000102606   ENSE00001236980   ENSE00000686833                     Rho guanine nucleotide exchange factor 7
  ATIC           ENSG00000138363   ENSE00001363573   ENSE00001146950                  Bifunctional purine biosynthesis protein PURH
  ATP5C1         ENSG00000165629   ENSE00001481323   ENSE00001094820                ATP synthase gamma chain, mitochondrial precursor
  C2             ENSG00000204364   ENSE00001467298   ENSE00001467293                             Complement C2 precursor
  C21orf33       ENSG00000160221   ENSE00001506662   ENSE00001506660                   ES1 protein homolog, mitochondrial precursor
  C3             ENSG00000125730   ENSE00001053527   ENSE00000858107                             Complement C3 precursor
  C3             ENSG00000125730   ENSE00001053551   ENSE00000858104                             Complement C3 precursor
  CCT5           ENSG00000150753   ENSE00001082664   ENSE00001082663                       T-complex protein 1 subunit epsilon
  CD109          ENSG00000156535   ENSE00001144336   ENSE00001144250                             CD109 antigen precursor
  CD109          ENSG00000156535   ENSE00001144243   ENSE00001084417                             CD109 antigen precursor
  CLTC           ENSG00000141367   ENSE00000948100   ENSE00000948105                              Clathrin heavy chain 1
  CLTCL1         ENSG00000070371   ENSE00000596272   ENSE00001343357                              Clathrin heavy chain 2
  COL14A1        ENSG00000187955   ENSE00001022732   ENSE00001090753                                 Collagen alpha-1
  COL14A1        ENSG00000187955   ENSE00000702894   ENSE00001476378                                 Collagen alpha-1
  COPB1          ENSG00000129083   ENSE00000886038   ENSE00000703797                              Coatomer subunit beta
  COPB2          ENSG00000184432   ENSE00001322263   ENSE00001311447                              Coatomer subunit beta
  CP             ENSG00000047457   ENSE00001008190   ENSE00000779559                             Ceruloplasmin precursor
  CSE1L          ENSG00000124207   ENSE00000845497   ENSE00000845507                                    Exportin-2
  CYFIP1         ENSG00000068793   ENSE00000883355   ENSE00000883353                      Cytoplasmic FMR1-interacting protein 1
  DCTN1          ENSG00000204843   ENSE00001261315   ENSE00001199793                                    Dynactin-1
  ENO1           ENSG00000074800   ENSE00000739712   ENSE00000738913                                  Alpha-enolase
  FAM62A         ENSG00000139641   ENSE00000939452   ENSE00000939471                                  Protein FAM62A
  FH             ENSG00000091483   ENSE00000961691   ENSE00001069123                   Fumarate hydratase, mitochondrial precursor
  FLII           ENSG00000177731   ENSE00001289389   ENSE00001289270                          Protein flightless-1 homolog.
  FLNA           ENSG00000196924   ENSE00000678331   ENSE00000868362                                    Filamin-A
  GLUD1          ENSG00000148672   ENSE00000986500   ENSE00000986506                Glutamate dehydrogenase 1, mitochondrial precursor
  GPD2           ENSG00000115159   ENSE00000924640   ENSE00001188495           Glycerol-3-phosphate dehydrogenase, mitochondrial precursor
  GUCY1A3        ENSG00000164116   ENSE00001231799   ENSE00001081588                    Guanylate cyclase soluble subunit alpha-3
  HD             ENSG00000197386   ENSE00000854949   ENSE00000854981                            Huntington disease protein
  HD             ENSG00000197386   ENSE00000854965   ENSE00001251513                            Huntington disease protein
  HD             ENSG00000197386   ENSE00000854958   ENSE00000854991                            Huntington disease protein
  HD             ENSG00000197386   ENSE00000854979   ENSE00000855002                            Huntington disease protein
  HERC2          ENSG00000128731   ENSE00000672196   ENSE00001275912                    Probable E3 ubiquitin-protein ligase HERC2
  HERC2          ENSG00000128731   ENSE00000672179   ENSE00001275876                    Probable E3 ubiquitin-protein ligase HERC2
  HERC2          ENSG00000128731   ENSE00000908550   ENSE00000908562                    Probable E3 ubiquitin-protein ligase HERC2
  HK1            ENSG00000156515   ENSE00001145338   ENSE00001276961                                   Hexokinase-1
  HSD17B4        ENSG00000133835   ENSE00001143964   ENSE00000972282                    Peroxisomal multifunctional enzyme type 2
  HSD17B4        ENSG00000133835   ENSE00001143927   ENSE00000972282                    Peroxisomal multifunctional enzyme type 2
  HSD17B4        ENSG00000133835   ENSE00001169924   ENSE00001144014                    Peroxisomal multifunctional enzyme type 2
  HSD17B4        ENSG00000133835   ENSE00001143964   ENSE00001143927                    Peroxisomal multifunctional enzyme type 2
  HYOU1          ENSG00000149428   ENSE00001195270   ENSE00000990519                    150 kDa oxygen-regulated protein precursor
  IQGAP2         ENSG00000145703   ENSE00000971759   ENSE00001030776                    Ras GTPase-activating-like protein IQGAP2.
  ITGA2          ENSG00000164171   ENSE00001082079   ENSE00001082066                            Integrin alpha-2 precursor
  ITGA2          ENSG00000164171   ENSE00001082085   ENSE00001082079                            Integrin alpha-2 precursor
  ITGB3          ENSG00000056345   ENSE00000947489   ENSE00000735016                            Integrin beta-3 precursor
  ITIH2          ENSG00000151655   ENSE00001415117   ENSE00001395332              Inter-alpha-trypsin inhibitor heavy chain H2 precursor
  ITPR1          ENSG00000150995   ENSE00001072653   ENSE00001122088                   Inositol 1,4,5-trisphosphate receptor type 1
  KIF5B          ENSG00000170759   ENSE00001163763   ENSE00001163716                               Kinesin heavy chain
  KRT16          ENSG00000186832   ENSE00001118312   ENSE00001118295                         Keratin, type I cytoskeletal 16
  KTN1           ENSG00000126777   ENSE00001292736   ENSE00000867340                                     Kinectin
  LCP2           ENSG00000043462   ENSE00000769281   ENSE00000812799                          Lymphocyte cytosolic protein 2
  LRRFIP2        ENSG00000093167   ENSE00000825531   ENSE00000760563               Leucine-rich repeat flightless-interacting protein 2
  LTBP1          ENSG00000049323   ENSE00000932484   ENSE00000932488   Latent-transforming growth factor beta-binding protein, isoform 1L precursor
  LTBP1          ENSG00000049323   ENSE00000932483   ENSE00001006678   Latent-transforming growth factor beta-binding protein, isoform 1L precursor
  LTBP1          ENSG00000049323   ENSE00000932485   ENSE00000744639   Latent-transforming growth factor beta-binding protein, isoform 1L precursor
  LTBP1          ENSG00000049323   ENSE00000809557   ENSE00000744639   Latent-transforming growth factor beta-binding protein, isoform 1L precursor
  MACF1          ENSG00000127603   ENSE00001041391   ENSE00001079474            Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5
  MACF1          ENSG00000127603   ENSE00001408360   ENSE00001218066            Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5
  MACF1          ENSG00000127603   ENSE00001411283   ENSE00001218029            Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5
  MACF1          ENSG00000127603   ENSE00001411283   ENSE00001041391            Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5
  MMRN1          ENSG00000138722   ENSE00001003940   ENSE00001003943                              Multimerin-1 precursor
  MTCH2          ENSG00000109919   ENSE00000714864   ENSE00001267224                         Mitochondrial carrier homolog 2
  MTHFD1         ENSG00000100714   ENSE00000658410   ENSE00000658424                    C-1-tetrahydrofolate synthase, cytoplasmic
  MTHFD1         ENSG00000100714   ENSE00000658406   ENSE00000658420                    C-1-tetrahydrofolate synthase, cytoplasmic
  MYH4           ENSG00000141048   ENSE00000907666   ENSE00000907657                                     Myosin-4
  NID2           ENSG00000087303   ENSE00000854715   ENSE00000657316                               Nidogen-2 precursor
  NID2           ENSG00000087303   ENSE00000657316   ENSE00000854708                               Nidogen-2 precursor
  NPEPPS         ENSG00000141279   ENSE00001138170   ENSE00001138132                        Puromycin-sensitive aminopeptidase
  NRBP1          ENSG00000115216   ENSE00000809167   ENSE00000733215                        Nuclear receptor-binding protein.
  OGDH           ENSG00000105953   ENSE00000681534   ENSE00000681548        2-oxoglutarate dehydrogenase E1 component, mitochondrial precursor
  PDIA5          ENSG00000065485   ENSE00001149277   ENSE00001353839                     Protein disulfide-isomerase A5 precursor
  PICALM         ENSG00000073921   ENSE00000742961   ENSE00001376469              Phosphatidylinositol-binding clathrin assembly protein
  PIP5K2A        ENSG00000150867   ENSE00000996551   ENSE00000996552              Phosphatidylinositol-4-phosphate 5-kinase type-2 alpha
  PKHD1L1        ENSG00000205038   ENSE00001477427   ENSE00001477413                                  fibrocystin L
  PKHD1L1        ENSG00000205038   ENSE00001477417   ENSE00001477394                                  fibrocystin L
  PKHD1L1        ENSG00000205038   ENSE00001477471   ENSE00001477421                                  fibrocystin L
  PKHD1L1        ENSG00000205038   ENSE00001477455   ENSE00001477439                                  fibrocystin L
  PKHD1L1        ENSG00000205038   ENSE00001477437   ENSE00001477347                                  fibrocystin L
  PKHD1L1        ENSG00000205038   ENSE00001477474   ENSE00001477449                                  fibrocystin L
  PLEC1          ENSG00000178209   ENSE00001244151   ENSE00001244041                                    Plectin-1
  PLEC1          ENSG00000178209   ENSE00001244070   ENSE00001295392                                    Plectin-1
  PLG            ENSG00000122194   ENSE00000828808   ENSE00001315450                              Plasminogen precursor
  PLXDC2         ENSG00000120594   ENSE00001137970   ENSE00000996527                   Plexin domain-containing protein 2 precursor
  PROS1          ENSG00000184500   ENSE00001142430   ENSE00001142413                     Vitamin K-dependent protein S precursor.
  PSMC6          ENSG00000100519   ENSE00000657442   ENSE00000657448                       26S protease regulatory subunit S10B
  PTPN18         ENSG00000072135   ENSE00000436095   ENSE00000776192                Tyrosine-protein phosphatase non-receptor type 18
  RAB8A          ENSG00000167461   ENSE00001113277   ENSE00001277163                            Ras-related protein Rab-8A
  RASA3          ENSG00000185989   ENSE00001334941   ENSE00001334928                         Ras GTPase-activating protein 3
  RTN2           ENSG00000125744   ENSE00000858227   ENSE00000858223                                   Reticulon-2
  SNX17          ENSG00000115234   ENSE00000734775   ENSE00000734780                                 Sorting nexin-17
  SNX17          ENSG00000115234   ENSE00000962998   ENSE00000734785                                 Sorting nexin-17
  SPTBN1         ENSG00000115306   ENSE00001036038   ENSE00001036017                           Spectrin beta chain, brain 1
  SRC            ENSG00000197122   ENSE00001390472   ENSE00000661882                    Proto-oncogene tyrosine-protein kinase Src
  STOM           ENSG00000148175   ENSE00000983575   ENSE00001262522                   Erythrocyte band 7 integral membrane protein
  THBS1          ENSG00000137801   ENSE00000883758   ENSE00000883772                            Thrombospondin-1 precursor
  TMEM33         ENSG00000109133   ENSE00001489658   ENSE00000712706                             Transmembrane protein 33
  TMOD3          ENSG00000138594   ENSE00001170748   ENSE00001102815                                  Tropomodulin-3
  TPD52L2        ENSG00000101150   ENSE00000663594   ENSE00001391722                                Tumor protein D54
  UBASH3B        ENSG00000154127   ENSE00001014167   ENSE00001014158                    Suppressor of T-cell receptor signaling 1
  UBE1L          ENSG00000182179   ENSE00001305417   ENSE00001306981                      Ubiquitin-activating enzyme E1 homolog
  UGCGL1         ENSG00000136731   ENSE00001148961   ENSE00001206051             UDP-glucose:glycoprotein glucosyltransferase 1 precursor
  UGP2           ENSG00000169764   ENSE00001189522   ENSE00001165982                  UTP--glucose-1-phosphate uridylyltransferase 2
  UNC13D         ENSG00000092929   ENSE00001227797   ENSE00001406672                                 Unc-13 homolog D
  UNC13D         ENSG00000092929   ENSE00001227615   ENSE00001430590                                 Unc-13 homolog D
  USP14          ENSG00000101557   ENSE00001208659   ENSE00001252715                     Ubiquitin carboxyl-terminal hydrolase 14
  VPS13A         ENSG00000197969   ENSE00001024130   ENSE00000803886                 Vacuolar protein sorting-associated protein 13A
  VPS13A         ENSG00000197969   ENSE00001024085   ENSE00000708339                 Vacuolar protein sorting-associated protein 13A
  VPS13A         ENSG00000197969   ENSE00000708190   ENSE00000708458                 Vacuolar protein sorting-associated protein 13A
  VPS13A         ENSG00000197969   ENSE00001171911   ENSE00000803905                 Vacuolar protein sorting-associated protein 13A
  VPS13A         ENSG00000197969   ENSE00001024110   ENSE00000708298                 Vacuolar protein sorting-associated protein 13A
  VPS13A         ENSG00000197969   ENSE00001024141   ENSE00001024126                 Vacuolar protein sorting-associated protein 13A
  VPS13A         ENSG00000197969   ENSE00001024130   ENSE00000707929                 Vacuolar protein sorting-associated protein 13A
  VPS13C         ENSG00000129003   ENSE00001124918   ENSE00000885044                 Vacuolar protein sorting-associated protein 13C.
  VPS13C         ENSG00000129003   ENSE00001124912   ENSE00001364815                 Vacuolar protein sorting-associated protein 13C.
  VPS13C         ENSG00000129003   ENSE00000449795   ENSE00001380396                 Vacuolar protein sorting-associated protein 13C.
  VPS13C         ENSG00000129003   ENSE00000885045   ENSE00001368990                 Vacuolar protein sorting-associated protein 13C.
  VPS13C         ENSG00000129003   ENSE00000885061   ENSE00001484949                 Vacuolar protein sorting-associated protein 13C.
  VPS13C         ENSG00000129003   ENSE00000885061   ENSE00000885051                 Vacuolar protein sorting-associated protein 13C.
  WAS            ENSG00000015285   ENSE00000669947   ENSE00001255082                         Wiskott-Aldrich syndrome protein
  WDR44          ENSG00000131725   ENSE00000899838   ENSE00000899846                               WD repeat protein 44

The Gene symbol, Ensembl gene and exon identifiers and the gene descriptions are listed for all 129 junctions found in 89 genes. The exon identifiers one and two indicate the exons involved in the junction peptide identified in SkipE.

Verification of splice variants at mRNA level {#s2c}
---------------------------------------------

We confirmed the presence of several mRNA species encoding previously undescribed exon skip events by RT-PCR and sequencing of the products. We chose 3 junctions identified in the SkipE data for which evidence of protein expression was obtained in the IPI search ([Fig. 4](#pone-0005001-g004){ref-type="fig"} **)**. The proteins chosen were integrin alpha 2 or platelet glycoprotein Ia (*ITGA2*), fumarate hydratase (*FH*) and puromycin-sensitive aminopeptidase (*NPEPPS*). These proteins represent different compartments and perform various roles in the cell.

![Exon skip events verified at mRNA level.\
Each numbered box represents an exon and the position in the gene. The skip event is indicated by the diagonal lines. The parallelograms enclose the portion of amino acid sequence that is absent from the novel splice isoform. The bold and underlined form the junction peptides.](pone.0005001.g004){#pone-0005001-g004}

*ITGA2* forms part of a platelet collagen receptor, involved in the initial adhesion of platelets to extracellular matrix exposed at sites of endothelial injury, such as atherosclerotic lesions [@pone.0005001-Santoro1], [@pone.0005001-Holtkotter1]. Splice variants may be functionally significant: a platelet-specific splice variant may allow some tissue specific functions, while polymorphic variations in *ITGA2* are associated with risk of thrombotic stroke [@pone.0005001-Matarin1]. The junction peptide we identified, which was formed by splicing exon 26 to exon 29, occurred 3 times in the SkipE data and 16 peptides were present for this protein in the IPI data. This splicing event results in the deletion of 68 amino acids proximal to the single transmembrane domain on the extracellular surface, far from any reported ligand-binding domains. Similar changes in the length of the 'stalk' of the platelet adhesion receptor GPIb are reported to affect the ability of platelets to adhere at high flow rates [@pone.0005001-Ozelo1].

*FH* is a Krebs\' cycle enzyme which is located in the cytosol or can be transported to the mitochondrion and has been shown to act as a tumor suppressor [@pone.0005001-Rustin1]. The *FH* junction under study was formed by splicing exon 2 to exon 6 and was identified 5 times with 7 different peptides identified in the IPI data.

The final protein selected, *NPEPPS*, is a puromycin-sensitive aminopeptidase, common in brain and immune tissues. NPEPPS may play a role in cell development and cell cycle-regulating proteolysis [@pone.0005001-Constam1]. The *NPEPPS* junction identified was created *via* the splicing of exon 10 to exon 17 and occurred 4 times while 4 peptides were identified in IPI sequences.

The NPEPPS event was the longest skip we investigated, removing 6 exons. Interestingly, skips of up to 96 exons were observed -- the distribution of skip lengths shown in [Fig. 5](#pone-0005001-g005){ref-type="fig"} is highly reminiscent of that observed by Sultan *et al*. in mRNAseq data [@pone.0005001-Sultan1]. Such long skips remain to be verified (perhaps by the use of 2-dimensional gel separation followed by Western blotting and/or MS), as the number of other potential AS events in genes exhibiting long range AS gives rise to multiple PCR products (data not shown). Primer pairs specific to the exons involved in each junction generated multiple or ambiguous products with a predominant band migrating at the "canonical" amplicon length. It is likely that the AS message is present in relatively small amounts and is out-competed by the canonical isoform in PCR. Therefore, we designed primers to span the novel junctions and paired them with compatible reverse primers providing a skip-specific PCR primer pair ([Table 2](#pone-0005001-t002){ref-type="table"}).

![Frequency distribution of exon skip lengths identified in the SkipE database.\
The number of occurrences of each skip length identified is shown.](pone.0005001.g005){#pone-0005001-g005}

10.1371/journal.pone.0005001.t002

###### Design of exon-junction-spanning PCR primers.

![](pone.0005001.t002){#pone-0005001-t002-2}

  Gene        Junction Peptide   Junction Primer   Product Length (bp)                                         
  ---------- ------------------ ----------------- --------------------- ----- ----- ---- ----- ----- ----- --- -----
  *NPEPPS*    AQELDALDNSHPIEAR          T                  CCT           ATT   GAA   --   GCT   CGA   GCT   G   200
                                                            P             I     E          A     R             
  *FH*          MPEFSGYVQQVK           AA                  CGC           ATG   CCA   --   GAA   TTT   AGT   G   165
                                                                          M     P          E     F     S       
  *ITGA2*      ELIPLMIMKPDEK           CC                  AAA           GAA   TTG   --   ATT   CCC   CTG   A   115
                                                                          E     L          I     P     L       

The gene symbol, junction peptide sequence, junction primer and product length are shown. The junction primer column indicates, with a dash, the exon-exon boundary.

PCR products of the expected sizes were observed in each case with cDNA derived both from platelets and from their precursors, megakaryocytes. The bands derived from platelet cDNA were excised and the sequence verified that the predicted products were obtained. It can be seen from [Figure 6](#pone-0005001-g006){ref-type="fig"} that the megakaryocyte template produced a greater quantity of the amplicon in each case, reflective of the availability of template rather than an increased proportion of AS message in these cells.

![Agarose gel electrophoresis of PCR products.\
Lanes 1--5 show products amplified from megakaryocyte cDNA; samples in lanes 6--10 contained template from platelets. Molecular size markers are in lane 11.](pone.0005001.g006){#pone-0005001-g006}

Discussion {#s3}
==========

Our findings demonstrate that many exon skip events, which have not been previously described, occur in platelets. These events have been found in a novel high-throughput fashion. The approach described is compatible with existing MS/MS software solutions accessible to the scientific community. We have shown that, while these events were found computationally, using a proteomics platform, we selected and verified three of them at the transcriptomic level by PCR and sequencing.

It is notable that the overlap of proteins, identified in the AS and IPI databases, is relatively low -- just 89 genes were represented by peptides in both datasets. In common with many other high-throughput experimental approaches such as yeast two-hybrid and protein interaction networking [@pone.0005001-Mestres1], [@pone.0005001-Yu1], MS/MS proteomics experiments suffer from a lack of completeness - that is, coverage of the proteome is neither absolute nor unbiased. The completeness of proteomics experiments is increased by high-throughput approaches although approximately 10 repetitions of a multidimensional protein identification technology (MudPIT) experiment are required to reach 95% analytical completeness [@pone.0005001-Durr1], [@pone.0005001-Liu1]. The proteins identified in any given experiment will be constrained by a number of factors including expression level and presence of proteotypic peptides [@pone.0005001-Mallick1]. In the case of splice isoforms, these will not necessarily correspond to the 'canonical' isoforms. Therefore, although, in this experiment we used IPI-based detection of protein expression to filter potential targets for verification, it is clear that not all genes displaying AS will also be detected as canonical isoforms and *vice versa*. Although we applied a relatively strict cutoff of 0.9 to the SkipE hits, given the fact that they are subject to only PeptideProphet and not ProteinProphet validation, it is possible there are more false positives in the SkipE data than the IPI results. Ultra high throughput mRNAseq verification of high numbers of skip events detected in proteomics data will demonstrate the synergy derived from the combination of high-throughput techniques and these datasets will provide mutual cross validation.

It appears that the novel splice events detected in this study were most likely inherited from the precursor rather than being specific to the platelet. It will be interesting to determine the distribution of these events in a variety of cell types and tissues across different organisms. It will also be of interest to determine whether any of the exon skip events occur specifically in the platelet since it is known that splicing can occur in these cells, despite the absence of a nucleus. While exon skips are the most common type of AS event described to date [@pone.0005001-Wang2], [@pone.0005001-Sultan1], [@pone.0005001-Sugnet1], [@pone.0005001-Kim1], several other splicing patterns occur during transcription including alternative 5′ and 3′ splice sites and intron retention. These events require a different approach to detection in proteomics data. Clearly, intron-specific peptides could be incorporated into the SkipE database, though this would considerably increase the database size. A parallel intron peptide database would be a feasible approach. Alternative 5′ or 3′ splice sites on the other hand are not amenable to detection in this manner and require an alternative approach.

In conclusion, we have developed a novel database, suitable for the detection of alternative splicing in mass spectrometry data and shown that it can detect AS events in a platelet MS/MS dataset. The approach described augments current methodologies. Detection of AS directly at the protein level avoids any requirement for amplification steps and indicates that the events detected are indeed expressed. Millions of spectra, which are already available in both public and private repositories, can be reanalyzed using this database. As label-free quantitation tools are incorporated into proteomics pipelines, the added value becomes even greater as isoforms can be compared at the expression level within and between samples. Again, this approach is applicable to the vast repositories of data already gathered as well as to all new samples. The application of this methodology will rapidly give us new insights into AS throughout a range of tissue types and biological states. Since AS events have previously been associated with particular diseases, the approach described here will allow the discovery of disease-specific biomarkers at the splice isoform level. As the proteome is the network most closely related to the biological phenotype, the potential to discover clinically relevant biomarkers related to diagnosis, prognosis or susceptibility is immense, impacting on all levels of clinical practice and drug development.

Note added in proof {#s3a}
-------------------

During the review process a similar database development was described by Mo *et al*. [@pone.0005001-Mo1].

Materials and Methods {#s4}
=====================

Platelet MS/MS data acquisition {#s4a}
-------------------------------

Platelets were prepared as previously described in McRedmond *et al.* [@pone.0005001-McRedmond1] and incubated at 37°C with stirring. One sample was activated by the addition of 5 µM thrombin receptor activating peptide for 5 minutes. Resting and activated samples were separated into subcellular compartments using a ProteoExtract subcellular proteome extraction kit (Merck Biosciences, Nottingham, UK). The manufacturer\'s protocol was modified to ensure separation of platelet pellets from supernatants and to allow the recovery of released platelet proteins. This procedure yields a 'nuclear' fraction, which is artefactual when applied to platelets. Fractions from resting and thrombin receptor activating peptide-activated platelets were separated by SDS-PAGE; gel lanes were cut into 32 slices and digested with trypsin. Peptides were separated by single-dimension reverse-phase liquid chromatography and analysed using an LTQ ion trap mass spectrometer (Thermo-Finnigan, San Jose, CA) [@pone.0005001-Mathivanan1].

Public data repositories {#s4b}
------------------------

Ensembl version 46 was used to obtain all protein coding genes and sequences, along with their associated exon predictions for the human, mouse and rat genomes. Previously annotated AS events in our dataset were filtered out by comparing sequences with ASTD version 1.1 and IPI version 3.16 using Washington University basic local alignment search tool (WU-BLAST) version 2.0, applying the pam30 substitution matrix.

Database development {#s4c}
--------------------

Transcript and exon data were extracted, *via* the Perl-API, from Ensembl v46 for all annotated genes in each of the human, mouse and rat genomes. For each species, a separate database was generated. Briefly, a standard "full-length transcript" containing, for each exon position along the transcript, the longest predicted exon sequence was generated. This procedure yields a single, representative, "standard" transcript from which to design junction peptides. The junction peptides are the derived peptide sequences that span exon-exon junctions from the most C-terminal protease site in the upstream exon to the most N-terminal protease site in the downstream exon. In this case, we used trypsin as the protease. Only the junctions of non-consecutive exons were included in the database and the content was further constrained by only including junctions in which phase was maintained between exons. The fasta files for all three species are publicly available online at <http://bioinformatics.ucd.ie/SkipE>.

MS/MS data analysis {#s4d}
-------------------

All MS/MS data analyses were carried out using the Proline proteomics platform (Biontrack, Dublin <http://www.biontrack.com>). Spectra were compared against databases using SEQUEST [@pone.0005001-Eng1]. Validation of peptides and proteins was carried out using the transproteomics pipeline tools PeptideProphet and ProteinProphet [@pone.0005001-Keller1], respectively, and filtered with a cut-off of P\>0.9.

RNA isolation {#s4e}
-------------

RNA from platelet and the megakaryocytic cell line Meg-01 was isolated as previously described [@pone.0005001-McRedmond1] and reverse-transcribed into cDNA using standard techniques.

Validation {#s4f}
----------

PCR and sequencing was carried out to validate the alternative splicing events. All primer synthesis and sequencing was carried out by MWG biotech (<http://www.eurofinsdna.com/>). Primer sequences for *ITGA2* were, forward CAAAGAATTGATTCCCCTGA and reverse TGCAACCAGAGCTAACAGCA. *NPEPPS* forward primer is TCCTATTGAAGCTCGAGCTG and reverse CAGCCCAGTCTCTCCCCTAT and *FH* forward primer is AACGCATGCCAGAATTTAGTG and reverse is CCACTTTTGCAGCAACCTTT. The PCR reactions were made up as follows; 8 µl 5× GoTaq buffer, 1 µl Taq polymerase, 2 µl 4 mM dNTPs (Promega), 22 µl H2O, 2 µl primers and 1.5 µl template. The following PCR conditions were used: 2 minutes of denaturation at 94°C followed by 40 cycles of 30 seconds denaturing at 94°C, 30 seconds annealing at 55°C for *NPEPPS* and 58°C for *FH* and *ITGA2* and a 90 second extension at 72°C followed by incubation at 4°C. Products were separated on 2% agarose gels. Positive control was integrin *ITGA2*B (α2B), a known abundant platelet glycoprotein. Negative control was a no-template RT reaction.

Supporting Information {#s5}
======================

###### 

Characteristics of the contents and constraints applied to create the species-specific SkipE databases.

(0.03 MB DOC)

###### 

Click here for additional data file.

###### 

Numbers of platelet peptide and protein identifications in IPI and SkipE databases

(0.03 MB DOC)

###### 

Click here for additional data file.

###### 

KEGG annotations for all of the 89 genes found to be alternatively spliced and represented in the IPI data. In total, 32 pathways were found. These pathways are sorted by impact factor, a probabilistic term which is calculated from the number of genes in the input file, the size of the reference chip (U133 plus2.0), the number of input genes that are on a given pathway and the number of the pathway genes represented on the reference chip.

(0.08 MB DOC)

###### 

Click here for additional data file.

###### 

KEGG annotations for all the genes found in IPI. In total, 78 pathways were found. These pathways are sorted by impact factor, a probabilistic term which is calculated from the number of genes in the input file, the size of the reference chip (U133 plus2.0), the number of input genes that are on a given pathway and the number of the pathway genes represented on the reference chip.

(0.17 MB DOC)

###### 

Click here for additional data file.
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